Related references
Note: Only part of the references are listed.Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis A Living Systematic Review and Network Meta-analysis for the American College of Physicians
Chelsea Ayers et al.
ANNALS OF INTERNAL MEDICINE (2023)
Importance of Time Point-Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses
Damon Willems et al.
CLINICAL THERAPEUTICS (2022)
Drug therapy for osteoporosis in older adults
Ian R Reid et al.
LANCET (2022)
Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS
Elena Tsourdi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Association between mortality risk and the number, location, and sequence of subsequent fractures in the elderly
S-B Lee et al.
OSTEOPOROSIS INTERNATIONAL (2021)
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
Nannan Li et al.
PHARMACOECONOMICS (2021)
Osteoporosis Recent Recommendations and Positions of the American Society for Bone and Mineral Research and the International Society for Clinical Densitometry
Paul A. Anderson et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2021)
Diminishing Value from Multiple Serial Bone Densitometry in Women Receiving Antiresorptive Medication for Osteoporosis
Gregory A. Kline et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines A report for the National Osteoporosis Guideline Group (NOGG)
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2021)
A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05
H. Hagino et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
Annika Vestergaard Kvist et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis
Filippo Migliorini et al.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH (2021)
Refracture and mortality following hospitalization for severe osteoporotic fractures: The Fractos Study
Christian Roux et al.
JBMR PLUS (2021)
After the initial fracture in postmenopausal women, where do subsequent fractures occur?
Carolyn J. Crandall et al.
ECLINICALMEDICINE (2021)
Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women
Oth Tran et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis
Shannon A. Miller et al.
JOURNAL OF PHARMACY TECHNOLOGY (2021)
Diminishing Value from Multiple Serial Bone Densitometry in Women Receiving Antiresorptive Medication for Osteoporosis
Gregory A. Kline et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis
E. L. Simpson et al.
BONE (2020)
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis
Fang Lv et al.
BONE (2020)
Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study
Houchen Lyu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Management of Male Breast Cancer: ASCO Guideline
Michael J. Hassett et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis
Sara Kaveh et al.
CLINICAL RHEUMATOLOGY (2020)
The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women
D. Sanchez-Rodriguez et al.
MATURITAS (2020)
Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis A Population-Based Cohort Study
Houchen Lyu et al.
ANNALS OF INTERNAL MEDICINE (2020)
Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
Sarah Davis et al.
HEALTH TECHNOLOGY ASSESSMENT (2020)
Diagnosis and management of osteoporosis in postmenopausal women in Gulf Cooperation Council (GCC) countries: consensus statement of the GCC countries' osteoporosis societies under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
Yousef Al-Saleh et al.
ARCHIVES OF OSTEOPOROSIS (2020)
Letter to the Editor: Delayed Denosumab Injections and Bone Mineral Density Response: En Electronic Health Record-Based Study
Gherardo Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
Susan L. Greenspan et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2020)
Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
Quang A. Le et al.
ANNALS OF PHARMACOTHERAPY (2019)
Women's Values and Preferences Regarding Osteoporosis Treatments: A Systematic Review
Patricia Barrionuevo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial
I. R. Reid et al.
JOURNAL OF INTERNAL MEDICINE (2019)
Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression
C. Beaudoin et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention A Systematic Review
Howard A. Fink et al.
ANNALS OF INTERNAL MEDICINE (2019)
The Development of Clinical Guidelines and Guidance Statements by the Clinical Guidelines Committee of the American College of Physicians: Update of Methods
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2019)
Disclosure of Interests and Management of Conflicts of Interest in Clinical Guidelines and Guidance Statements: Methods From the Clinical Guidelines Committee of the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2019)
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
Charles L. Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective
Theresa Kehoe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation
M. Hiligsmann et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture
Mickael Hiligsmann et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Cost-Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate-Alone Strategies in High-Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
Takahiro Mori et al.
JBMR PLUS (2019)
Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis
Joseph Sargon Joseph et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients
Paige Morizio et al.
ANNALS OF PHARMACOTHERAPY (2018)
Screening for Osteoporosis to Prevent Fractures US Preventive Services Task Force Recommendation Statement
Susan J. Curry et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Michael R. McClung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis
E. Michael Lewiecki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Does the Association of Comorbidity with 1-Year Mortality After Hip Fracture Differ According to Gender? The Norwegian Epidemiologic Osteoporosis Studies (NOREPOS)
Brit Solvor L. Riska et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2018)
Fracture Prevention with Zoledronate in Older Women with Osteopenia
Ian R. Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
T. Nakamura et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Overview of Fracture Prediction Tools
John A. Kanis et al.
JOURNAL OF CLINICAL DENSITOMETRY (2017)
Worldwide Fracture Prediction
Ghada El-Hajj Fuleihan et al.
JOURNAL OF CLINICAL DENSITOMETRY (2017)
Living systematic reviews: 4. Living guideline recommendations
Elie A. Akl et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2017)
Osteoporosis management in patients with breast cancer: EMAS position statement
Florence A. Tremollieres et al.
MATURITAS (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Trends in osteoporosis and low bone mass in older US adults, 2005-2006 through 2013-2014
A. C. Looker et al.
OSTEOPOROSIS INTERNATIONAL (2017)
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS
Stewart G. Albert et al.
ENDOCRINE PRACTICE (2017)
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2017)
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis A Randomized Clinical Trial
Paul D. Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis
Andrea Marques et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Benjamin Z. Leder et al.
LANCET (2015)
Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective
Stuart Silverman et al.
JOURNAL OF OSTEOPOROSIS (2015)
Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis
Takuo Fujita et al.
CALCIFIED TISSUE INTERNATIONAL (2014)
The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine
Nicole C. Wright et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis
Toshitaka Nakamura et al.
CALCIFIED TISSUE INTERNATIONAL (2013)
Combination therapy with risedronate and teriparatide in male osteoporosis
Marcella D. Walker et al.
ENDOCRINE (2013)
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis
Michael R. McClung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk
Toshitaka Nakamura et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis
Steven Boonen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Male osteoporosis: A review
Antonio Herrera et al.
WORLD JOURNAL OF ORTHOPEDICS (2012)
Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture
Steven Boonen et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2011)
Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival
Pia Nimann Kannegaard et al.
AGE AND AGEING (2010)
Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians (vol 148, pg 680, 2008)
A. Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2008)
Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2008)
Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2008)
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025
Russel Burge et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
